Skip to main content
      “Hey PRESTO!” – Early identification of psoriatic arthritis

      The past decade has seen the management of psoriatic

      Dr. John Cush RheumNow

      1 year 10 months ago
      “Hey PRESTO!” – Early identification of psoriatic arthritis The past decade has seen the management of psoriatic arthritis (PsA) transform, with our rich therapeutic armamentarium truly revolutionising patient outcomes. https://t.co/FJNX3mGCoy https://t.co/Whd8QKwmkU
      Effect of voclosporin in class V lupus nephritis

      Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22.

      Dr. John Cush RheumNow

      1 year 10 months ago
      Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/v716QGx73g https://t.co/ANTOEDAAHt
      The CONSUL Trial: Ankylosing Spondylitis

      Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22.

      Dr. John Cush RheumNow

      1 year 10 months ago
      The CONSUL Trial: Ankylosing Spondylitis Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22. https://t.co/DXTn3XfEzC https://t.co/pbORtBsRm2
      JAK vs TNF inhibitor Infections in RA

      Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. A

      Dr. John Cush RheumNow

      1 year 10 months ago
      JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/GsOsWtuT7v https://t.co/GloKEcB75L
      Does BASDAI work for women?

      In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured diseas

      Dr. John Cush RheumNow

      1 year 10 months ago
      Does BASDAI work for women? In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured disease activity and quality of life in female axSpA patients. Read more from Dr. Rachel Tate ( @uptoTate ) #ACR22 https://t.co/yWzdRMPgpp https://t.co/YrMsAYbAWN
      For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
      In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.
      Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus. However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials have been inconsistent.
      ACR Best Abstracts - Day 3

      The last day was jammed with important reports and research including the late breaking ab

      Dr. John Cush RheumNow

      1 year 10 months ago
      ACR Best Abstracts - Day 3 The last day was jammed with important reports and research including the late breaking abstracts. These were some of our favorites. #ACR22 https://t.co/vUrxBTF3Wj https://t.co/QKpTjyFfxt
      Best of ACR22 in PsA: Day Three
      RT @ericdeinmd: #ACR22 final plenary session
      10 week study outcomes of Philly vs Placebo to be reported
      #rheumpix @Rheum

      Eric Dein ericdeinmd

      1 year 10 months ago
      #ACR22 final plenary session 10 week study outcomes of Philly vs Placebo to be reported #rheumpix @RheumNow https://t.co/BradH2Ty70